Finance

Beta
Lists
GUTS:NASDAQ
Fractyl Health Inc
$0.80
+7.08%
(+0.053) 1D
$0.78
-1.96% (-0.016)
After hours
Closed: Jun 29, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GUTS...
Open
$0.76
High
$0.80
Low
$0.75
Mkt. cap
126.73M
Avg. vol.
1.88M
Volume
531.42K
52-wk high
$2.44
52-wk low
$0.38
EPS
-$1.53
Shares outstanding
158.65M
No. of employees
100
Open
$0.76
High
$0.80
Low
$0.75
Mkt. cap
126.73M
Avg. vol.
1.88M
Volume
531.42K
52-wk high
$2.44
52-wk low
$0.38
EPS
-$1.53
Shares outstanding
158.65M
No. of employees
100
News stories
From sources across the web
Profile
Fractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1. Wikipedia
About Fractyl Health Inc
CEO-
Employees100
Founded2010
HeadquartersBurlington, Massachusetts, United States
SectorMedical device
Websitefractyl.com
Analyst ratings
Based on 4 analysts giving stock ratings to GUTS in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for GUTS in the last 3 months.
Highest
Current $0.80
$8.00 (+905.53%)
Average
$5.00 (+528.46%)
Lowest
$2.00 (+151.38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ulz
Morgan Stanley
Hold
Maintained
$2.00
+151.4%
06/04/2026
Whitney Ijem
Canaccord Genuity
Buy
Reiterated
$8.00
+905.5%
06/05/2026
Joseph Pantginis
H.C. Wainwright
Buy
Maintained
$8.00
+905.5%
06/04/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$2.00
+151.4%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
21.15M
17.46M
16.49M
15.60M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.93M
5.24M
6.79M
5.22M
Operating expense
26.08M
22.69M
23.28M
20.82M
Total operating expenses
26.08M
22.69M
23.28M
20.82M
Operating income
-26.08M
-22.69M
-23.28M
-20.82M
Other non operating income
-363.00K
-21.21M
-20.19M
30.06M
EBT including unusual items
-27.89M
-45.60M
-43.73M
9.22M
EBT excluding unusual items
-26.22M
-43.74M
-42.83M
9.83M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-27.89M
-45.60M
-43.73M
9.22M
Net profit margin
-
-
-
-
Earnings per share
-0.57
-0.71
-0.07
-0.13
Interest and investment income
226.00K
166.00K
645.00K
593.00K
Interest expense
-
-
-
-
Net interest expenses
226.00K
166.00K
645.00K
593.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.81M
-22.40M
-23.00M
-20.54M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer